Company Description
Seaport Therapeutics, Inc., a clinical-stage therapeutics company, focuses on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders.
It is leveraging its proprietary Glyph platform to advance a pipeline of therapies to address the unmet needs in depression and anxiety.
The company’s lead product candidate, GlyphAllo (SPT-300 or Glyph Allopregnanolone), is a novel, Glyphed oral prodrug of allopregnanolone, an endogenous molecule that has been clinically validated in third-party trials for the treatment of postpartum depression.
Its second product candidate, GlyphAgo (SPT-320 or Glyph Agomelatine), is a novel, Glyphed oral prodrug of agomelatine, a clinically validated anxiolytic and antidepressant that is approved for the treatment of generalized anxiety disorder in Australia and major depressive disorder in Australia and the European Union.
The company was founded in 2024 and is based in Boston, Massachusetts.
| Country | United States |
| Founded | 2024 |
| IPO Date | May 1, 2026 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 58 |
| CEO | Daphne Zohar |
Contact Details
Address: 101 Seaport Blvd., Floor 12 Boston, Massachusetts 02210-2186 United States | |
| Phone | (617) 807-4062 |
| Website | seaporttx.com |
Stock Details
| Ticker Symbol | SPTX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 2042347 |
| CUSIP Number | 81221K108 |
| ISIN Number | US81221K1088 |
| Employer ID | 99-2235719 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Daphne Zohar | Founder, Chief Executive Officer, President and Director |
| Dr. Steven M. Paul M.D. | Founder and Non-Employee Chair of the Board |
| Dr. Michael Cunyuan Chen Ph.D. | Co-Founder and Chief Scientific Officer |
| Dr. Antony Loebel M.D. | Chief Medical Officer and President of Clinical Development |
| Lauren A. White M.B.A. | Chief Financial Officer |
| Lana Gladstein J.D. | General Counsel |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 8, 2026 | 10-Q | Quarterly Report |
| Jun 8, 2026 | 8-K | Current Report |
| May 11, 2026 | SCHEDULE 13D | Filing |
| May 11, 2026 | SCHEDULE 13G | Filing |
| May 6, 2026 | SCHEDULE 13D | Filing |
| May 4, 2026 | 8-K | Current Report |
| May 4, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| May 1, 2026 | 424B4 | Prospectus |
| Apr 30, 2026 | EFFECT | Notice of Effectiveness |
| Apr 30, 2026 | S-1MEF | Registration adding securities to prior Form S-1 registration |